Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer

Roelien Van De Vrie, Marianne J. Rutten, Joyce Danielle Asseler, Mariska Mg Leeflang, Gemma G. Kenter, Ben Willem J. Mol, Marrije Buist

Research output: Contribution to journalReview ArticleOtherpeer-review

4 Citations (Scopus)

Abstract

Background This is an update of a Cochrane Review that was originally published in 2014, Issue 2. The presence of residual disease after primary debulking surgery is a highly significant prognostic factor in women with advanced ovarian cancer. In up to 60%of women, residual tumour of > 1 cm is left behind after primary debulking surgery (defined as suboptimal debulking). These women might have benefited from neoadjuvant chemotherapy (NACT) prior to interval debulking surgery instead of primary debulking surgery followed by chemotherapy. It is therefore important to select accurately those women who would best be treated with primary debulking surgery followed by chemotherapy from those who would benefit from NACT prior to surgery. Objectives To determine if performing a laparoscopy, in addition to conventional diagnostic work-up, in women suspected of advanced ovarian cancer is accurate in predicting the resectability of disease. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 6) in the Cochrane Library; MEDLINE via Ovid, Embase via Ovid, MEDION and Science Citation Index and Conference Proceedings Citation Index (ISI Web of Science) to July 2018. We also checked references of identified primary studies and review articles. Selection criteria We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in women who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery.

Original languageEnglish
Article numberCD009786
Number of pages83
JournalCochrane Database of Systematic Reviews
Volume2019
Issue number3
DOIs
Publication statusPublished - 23 Mar 2019

Cite this

Van De Vrie, Roelien ; Rutten, Marianne J. ; Asseler, Joyce Danielle ; Leeflang, Mariska Mg ; Kenter, Gemma G. ; Mol, Ben Willem J. ; Buist, Marrije. / Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. In: Cochrane Database of Systematic Reviews. 2019 ; Vol. 2019, No. 3.
@article{6390ba93ad5d4727b24b1fa6993563c4,
title = "Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer",
abstract = "Background This is an update of a Cochrane Review that was originally published in 2014, Issue 2. The presence of residual disease after primary debulking surgery is a highly significant prognostic factor in women with advanced ovarian cancer. In up to 60{\%}of women, residual tumour of > 1 cm is left behind after primary debulking surgery (defined as suboptimal debulking). These women might have benefited from neoadjuvant chemotherapy (NACT) prior to interval debulking surgery instead of primary debulking surgery followed by chemotherapy. It is therefore important to select accurately those women who would best be treated with primary debulking surgery followed by chemotherapy from those who would benefit from NACT prior to surgery. Objectives To determine if performing a laparoscopy, in addition to conventional diagnostic work-up, in women suspected of advanced ovarian cancer is accurate in predicting the resectability of disease. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 6) in the Cochrane Library; MEDLINE via Ovid, Embase via Ovid, MEDION and Science Citation Index and Conference Proceedings Citation Index (ISI Web of Science) to July 2018. We also checked references of identified primary studies and review articles. Selection criteria We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in women who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery.",
author = "{Van De Vrie}, Roelien and Rutten, {Marianne J.} and Asseler, {Joyce Danielle} and Leeflang, {Mariska Mg} and Kenter, {Gemma G.} and Mol, {Ben Willem J.} and Marrije Buist",
year = "2019",
month = "3",
day = "23",
doi = "10.1002/14651858.CD009786.pub3",
language = "English",
volume = "2019",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",
publisher = "John Wiley & Sons",
number = "3",

}

Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. / Van De Vrie, Roelien; Rutten, Marianne J.; Asseler, Joyce Danielle; Leeflang, Mariska Mg; Kenter, Gemma G.; Mol, Ben Willem J.; Buist, Marrije.

In: Cochrane Database of Systematic Reviews, Vol. 2019, No. 3, CD009786, 23.03.2019.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer

AU - Van De Vrie, Roelien

AU - Rutten, Marianne J.

AU - Asseler, Joyce Danielle

AU - Leeflang, Mariska Mg

AU - Kenter, Gemma G.

AU - Mol, Ben Willem J.

AU - Buist, Marrije

PY - 2019/3/23

Y1 - 2019/3/23

N2 - Background This is an update of a Cochrane Review that was originally published in 2014, Issue 2. The presence of residual disease after primary debulking surgery is a highly significant prognostic factor in women with advanced ovarian cancer. In up to 60%of women, residual tumour of > 1 cm is left behind after primary debulking surgery (defined as suboptimal debulking). These women might have benefited from neoadjuvant chemotherapy (NACT) prior to interval debulking surgery instead of primary debulking surgery followed by chemotherapy. It is therefore important to select accurately those women who would best be treated with primary debulking surgery followed by chemotherapy from those who would benefit from NACT prior to surgery. Objectives To determine if performing a laparoscopy, in addition to conventional diagnostic work-up, in women suspected of advanced ovarian cancer is accurate in predicting the resectability of disease. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 6) in the Cochrane Library; MEDLINE via Ovid, Embase via Ovid, MEDION and Science Citation Index and Conference Proceedings Citation Index (ISI Web of Science) to July 2018. We also checked references of identified primary studies and review articles. Selection criteria We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in women who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery.

AB - Background This is an update of a Cochrane Review that was originally published in 2014, Issue 2. The presence of residual disease after primary debulking surgery is a highly significant prognostic factor in women with advanced ovarian cancer. In up to 60%of women, residual tumour of > 1 cm is left behind after primary debulking surgery (defined as suboptimal debulking). These women might have benefited from neoadjuvant chemotherapy (NACT) prior to interval debulking surgery instead of primary debulking surgery followed by chemotherapy. It is therefore important to select accurately those women who would best be treated with primary debulking surgery followed by chemotherapy from those who would benefit from NACT prior to surgery. Objectives To determine if performing a laparoscopy, in addition to conventional diagnostic work-up, in women suspected of advanced ovarian cancer is accurate in predicting the resectability of disease. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 6) in the Cochrane Library; MEDLINE via Ovid, Embase via Ovid, MEDION and Science Citation Index and Conference Proceedings Citation Index (ISI Web of Science) to July 2018. We also checked references of identified primary studies and review articles. Selection criteria We included studies that evaluated the diagnostic accuracy of laparoscopy to determine the resectability of disease in women who are suspected of advanced ovarian cancer and planned to receive primary debulking surgery.

UR - http://www.scopus.com/inward/record.url?scp=85063674460&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD009786.pub3

DO - 10.1002/14651858.CD009786.pub3

M3 - Review Article

VL - 2019

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 3

M1 - CD009786

ER -